Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) has been given a consensus recommendation of “Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.50.

A number of equities analysts have recently commented on APTO shares. Rodman & Renshaw started coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They set a “neutral” rating on the stock. ValuEngine upgraded shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. HC Wainwright started coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They set a “hold” rating on the stock. Finally, Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Monday, August 14th.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/17/aptose-biosciences-inc-apto-given-consensus-rating-of-buy-by-brokerages.html.

Aptose Biosciences (APTO) opened at 1.59 on Friday. The company has a 50-day moving average of $1.49 and a 200 day moving average of $1.24. Aptose Biosciences has a 52-week low of $0.78 and a 52-week high of $3.20. The company’s market cap is $38.20 million.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Equities research analysts predict that Aptose Biosciences will post ($1.09) EPS for the current year.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.